47 results about "Tumor margin" patented technology

A system and method for selectively treating aberrant cells such as cancer cells through administration of a train of electrical pulses is described. The pulse length and delay between successive pulses is optimized to produce effects on intracellular membrane potentials. Therapies based on the system and method produce two treatment zones: an ablation zone surrounding the electrodes within which aberrant cells are non-selectively killed and a selective treatment zone surrounding the ablation zone within which target cells are selectively killed through effects on intracellular membrane potentials. As a result, infiltrating tumor cells within a tumor margin can be effectively treated while sparing healthy tissue. The system and method are useful for treating various cancers in which solid tumors form and have a chance of recurrence from microscopic disease surrounding the tumor.

The present invention provides a minimally invasive, comprehensive same-day diagnosis and treatment method to remove tumor and ablate margins in breast cancer patients, comprising disease diagnosis by MRI and touch preparation cytology, followed by tumor removal and ablation of tumor margins.

Specular, ultrasonic, piezoelectric, detection devices provide real-time, analytical, edge finding in tissues during tumor surgery. Piezoelectric probe sensors at high frequencies (e.g., 10 to 100 MHz) characterize microstructure of cells and tissues. Through-transmission or specular reflection enables nondestructive testing in real time. Peak density analysis in power spectra, second-order spectrum analysis measuring the slope of the Fourier transform of the power spectrum, artificial intelligence pattern recognition, and modeling interpret the results. Model-based data analysis may compare experimental data with a computer simulation. Such comparisons may be based upon pattern classifications, including principal component analysis (PCA). Combining the above detection devices and analytical methods provides speed, accuracy, simplicity, and nondestructive mechanisms that militate for reliable, real-time diagnosis of tumor margins, tissue pathology, cell phenotypes, and molecular subtypes.

Methods and systems are provided for the detecting and presenting of faint signals from a real-time interactive imager. A real-time view of a subject is controlled by a user by entering commands that move the subject or a camera used to record the real-time view. The rate of this movement is monitored, and when the rate descends below a preset value, a trigger is sent to the camera. In response to the trigger, the camera switches to a lower frame frequency for capturing the real-time view of the subject, thereby increasing the amount of light collected in each frame, and increasing the sensitivity of the camera to faint signals. The methods and systems are particularly relevant for surgical or biopsy imaging, in which both a higher frame rate preview image of a subject for 3D visualization, and a higher sensitivity fluorescence image of the subject for tumor margin assessment, are desired.

Medical software tools platforms utilize a surgical display to provide access to specific medical software tools, such as medically-oriented applications or widgets, that can assist surgeons or surgical team in performing various procedures. In particular, an endoscopic camera may register the momentary rise in the optical signature reflected from a tissue surface and in turn transmit it to a medical image processing system which can also receive patient heart rate data and display relevant anomalies. Changes in various spectral components and the speed at which they change in relation to a source of stimulus (heartbeat, breathing, light source modulation, etc.) may indicate the arrival of blood, contrast agents or oxygen absorption. Combinations of these may indicate various states of differing disease or margins of tumors, and so forth. Also, changes in temperatures, physical dimensions, pressures, photoacoustic pressures and the rate of change may indicate tissue anomalies in comparison to historic values.

Medical software tools platforms utilize a surgical display to provide access to specific medical software tools, such as medically-oriented applications or widgets, that can assist surgeons or surgical team in performing various procedures. In particular, an endoscopic camera may register the momentary rise in the optical signature reflected from a tissue surface and in turn transmit it to a medical image processing system which can also receive patient heart rate data and display relevant anomalies. Changes in various spectral components and the speed at which they change in relation to a source of stimulus (heartbeat, breathing, light source modulation, etc.) may indicate the arrival of blood, contrast agents or oxygen absorption. Combinations of these may indicate various states of differing disease or margins of tumors, and so forth. Also, changes in temperatures, physical dimensions, pressures, photoacoustic pressures and the rate of change may indicate tissue anomalies in comparison to historic values.

The invention belongs to the field of computer-assisted surgery, and in particular relates to a brain tumor surgery incision locating and approach planning method which is used for incision localization and surgical approach planning before a brain tumor resection surgery on the basis of a medical image. The method comprises the following steps: acquiring a tumor central point; locating a point, which keeps the shortest distance from the tumor central point, on the scalp; locating a point, which keeps the shortest distance from the tumor central point, within a region; acquiring tumor marginal points; determining a surgical incision location; and designing a surgical approach. Compared with other methods of locating brain tumor on scalp, the method disclosed by the invention, under the circumstance of effectively avoiding intracranial important tissues, guarantees the shortest route of the designed surgical approach and meets the requirement of precise localization of incision with the minimum additional wound.

The invention provides a human colon cancer nude mouse skin subcutaneous transplantation tumor model establishing method. The method comprises the steps off cutting a tumor edge fish flesh shaped non-necrosis tumor tissue from a colon cancer specimen; shearing the tumor tissue into 0.8-1.3mm3 small blocks, performing primary transplantation and passage transplantation and finally studying individual specificity through a tumor model subjected to passage transplantation, such as the sensibility of a certain individual to chemotherapeutic drugs or radiotherapy.

A device having a biocompatible polymer as a body and regularly spaced radiation seeds and regularly spaced magnetic materials disposed of within the body of the biocompatible polymer, or uniformly distributed liquid radiation and magnetic fluid materials within a polymer slab, hollow thick wall polymer shell, or thin wall polymer balloon, as suitable for surgical placement within a resection cavity for treatment of at-risk tissue in the tumor margin with local hyperthermia in combination with radiation and potentially also with chemotherapy and/or immunotherapy that is slowly released from the biocompatible polymer.

The present invention provides a pharmaceutical composition that includes a) one or both of i) a peptide ligand that binds a zeta receptor and ii) at least one cancer chemotherapeutic agent; and b) a sustained release formulation. The invention also provides a combination including at least a portion of a tissue comprising one or more cells harboring a zeta receptor, such as a cancer cell or a precancerous cell, in contact with a pharmaceutical composition of the invention. Additionally the invention provides a method of treating a pathology that responds to a peptide ligand that binds a zeta receptor that includes a step of contacting a tissue characteristic of the pathology and containing cells harboring a zeta receptor, with a pharmaceutical composition of the invention. The invention further provides methods of inhibiting proliferation or metastasis of a cancer in a subject, including a) surgically excising a tumor characterizing the cancer from the subject; b) ensuring maximal removal of a tumor margin from the tumor site; and c) disposing a pharmaceutical composition of the invention upon a tissue remaining at a tumor margin wherein the tissue contains one or more tumor cells (such as a cancer cell or a precancerous cell) harboring a zeta receptor. The peptide ligand of a zeta receptor may be an enkephalin, an endorphin, a dynorphin, or a derivative thereof. Additionally the pharmaceutical composition may include one or more cancer chemotherapeutic agents.

The invention discloses a multi-blade collimator of a ray accelerator treatment head. The multi-blade collimator comprises a tank body which is arranged in a multi-layer manner, wherein openings whichpenetrate through the tank body are formed in the upper surface and the lower surface of each layer of the tank body; all the openings are coaxially formed and are used for enabling rays to penetrate; a plurality of vertical blades are arranged in each layer of the tank body; the blades are divided into two groups, and are respectively arranged on two ends of the tank body; the front ends of every two groups of the blades in the horizontal direction are opposite and are located at the corresponding opening; a driver is independently connected to the rear end in the horizontal direction of each blade; the blades in each group are sequentially arrayed, and the side surfaces of the blades are attached to each other; and a right angle beveling is arranged at the front end edge of the side surface of each blade. Through the adoption of the multi-blade collimator disclosed by the invention, multi-blade collimator can be more effectively attached to the edge of the tumor, so that better radiation field shape adapting effect is realized, radiation field shape adapting resolution is increased, ray radiation leakage is reduced, and radiation field transformation efficiency is improved. Theinvention also discloses tumor radiotherapy equipment comprising the multi-blade collimator of the ray accelerator treatment head.

The invention discloses a prior boundary-fused brain tumor segmentation method, and aims to overcome the defects that the generated brain tumor segmentation boundary is rough and the tumor is easy to reconstruct due to the fact that an existing convolutional network cannot fully utilize global image information. An optimal boundary of a tumor truth value is obtained from tumor prior knowledge, an optimal boundary generation network is constructed, an optimal boundary is added to a 3D U-net network of multiple down-sampling channels to carry out weight distribution and boundary enhancement on each layer of the network, and the similarity between a generated tumor edge and a tumor truth value edge is used as a loss item to be added to an original loss function to improve the accuracy of edge segmentation. According to the method, the prior knowledge is fused into the network and the loss function by using the tumor information of different modal nuclear magnetic images through multiple down-sampling channels, so that the comprehensiveness of tumor information utilization and the accuracy of tumor edge segmentation are improved.

The invention provides a method for dynamically adjusting the radioactive angle and dosage according to the movement of a tumor. According to the method, the moving position and spreading area of a dynamic tumor are precisely predicted and tracked, and the deflection of a radioactive angle is adjusted in time, and the radioactive dosage of a treatment target can be accurately controlled. The method comprises the following steps: (1) extracting the edge of a target tumor; (2) performing area related matching; (3) performing time grid clustering; (4) predicting the moving tumor position; and (5)adjusting the radioactive angle and dosage.

An apparatus for inspecting a biological tissue uses a pH-sensitive coating material to determine whether the tissue is normal or cancerous. The coating material is placed in contact with the tissue to be excited by an excitation light. The coating material is arranged to provide a response signal indicative of the pH value of the tissue. Using a fiber bundle having a plurality of optical fibers forming a linear array or a two-dimensional array adjacent the coating material, the imaging of localized surface pH in the biological tissue can be achieved using the response signal through each of the optical fibers. The fiber bundle can be arranged as a probe to examine the tissue for providing direct mapping of the tumor margin via a display, so that a surgeon can inspect the tissue in real-time.

A multimodal ultrasound/photoacoustic tumor margin detection system. The system can be comprised of an imaging and system control console, which can include an ultrasound and data acquisition subsystem including an ultrasound transmitter and receiver configured to transmit and receive ultrasonic energy. A host-control computer configured to provide a function generator function and a delay generation function can also be a part of the imaging and system control console.

We present a new method to automatically sample the tumour/stroma interface zone (IZ) from microscopy image analysis data. It first delineates the tumour edge using a set of explicit rules in grid-subsampled tissue areas; then the IZ of controlled width is sampled and ranked by the distance from the edge to compute TIL density profiles across the IZ. From this data, a set of novel Immunogradient indicators are computed to reflect TIL “gravitation” towards the tumour. We applied the method on CD8 immunohistochemistry images of surgically excised breast and colorectal cancers to predict overall patient survival. In both patient cohorts, we found strong and independent prognostic value of the Immunogradient indicators, outperforming methods currently available. We conclude that data-driven, automated, human operator-independent IZ sampling enables precise spatial immune response measurement in the tumour/host interaction frontline for prediction of disease and therapy outcomes.